Jun. 20 at 3:02 PM
$SLS $ABBV $BMY “Apogee'slead drug, zumilokibart, offers a longer-acting alternative to the blockbuster inflammatory medicine Dupixent, co-developed by Sanofi and Regeneron, which generated
$17.8bn in revenue last year.
While Dupixent is administered every two weeks, Apogee's drug is being studied in clinical trials as an injection given once every three to six months, offering a more convenient alternative to patients"
Why is this matters to SLS GPS?
GPS FDA approval will make
$ABBV Ventoclax Obsolete. GPS FDA approval will make
$BMY ONUREG Obsolete. Bidding war will be coming from multiple fronts from Multi Billion dollar patent protections from generic competitors to outdated toxic Drug Regimes that kill the patients before cancer does. GPS offer new drug that is not only Functionally Curative but also gives patients dignity with better quality of life. A paradigm shift in how cancer is treated moving forward. Patients first and foremost. ✌️🙏❤️🩹
